News
May 9, 2024
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
April 24, 2024
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
TScan Therapeutics Announces Exercise of Underwriters’ Option to Purchase Additional Shares
April 22, 2024
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 19, 2024
TScan Therapeutics Announces Closing of Upsized Public Offering
April 17, 2024
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
April 16, 2024
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
April 16, 2024
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
April 8, 2024
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
April 2, 2024